» Articles » PMID: 12183097

Opioid Antagonists: a Review of Their Role in Palliative Care, Focusing on Use in Opioid-related Constipation

Overview
Publisher Elsevier
Date 2002 Aug 17
PMID 12183097
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Opioid antagonists have well-established indications in the reversal of life-threatening opioid toxicity, but also hold considerable promise for other applications in palliative care practice, particularly management of opioid-related constipation. We briefly review current understanding of opioid receptors, focusing on their complex role in gastrointestinal physiology. We summarize the pharmacology, conventional indications, and clinical usage of three major groups of opioid antagonists, including a promising new peripherally acting agent, methylnaltrexone, which is not commercially available. We suggest an approach to administering opioid antagonists for reduction of life-threatening opioid toxicity in patients with pain. The literature on opioid-induced constipation and its treatment with opioid-antagonists is reviewed in detail. Finally, other potential uses of opioid antagonists in palliative care are described, especially strategies for reducing such opioid side effects as nausea and pruritus and for improving analgesia or reducing tolerance by concomitantly administrating both an opioid agonist and low dosages of an antagonist.

Citing Articles

Negative allosteric modulation of CB cannabinoid receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception.

Iyer V, Saberi S, Pacheco R, Sizemore E, Stockman S, Kulkarni A Neuropharmacology. 2024; 257:110052.

PMID: 38936657 PMC: 11261750. DOI: 10.1016/j.neuropharm.2024.110052.


Insights into the Current and Possible Future Use of Opioid Antagonists in Relation to Opioid-Induced Constipation and Dysbiosis.

Essmat N, Karadi D, Zador F, Kiraly K, Furst S, Al-Khrasani M Molecules. 2023; 28(23).

PMID: 38067494 PMC: 10708112. DOI: 10.3390/molecules28237766.


Impact of modified-release opioid use on clinical outcomes following total hip and knee arthroplasty: a propensity score-matched cohort study.

Liu S, Patanwala A, Naylor J, Levy N, Knaggs R, Stevens J Anaesthesia. 2023; 78(10):1237-1248.

PMID: 37365700 PMC: 10952779. DOI: 10.1111/anae.16070.


Does the combination of intrathecal fentanyl and morphine improve clinical outcomes in patients undergoing lumbar fusions?.

Villavicencio A, Taha H, Burneikiene S Neurosurg Rev. 2023; 46(1):97.

PMID: 37106209 DOI: 10.1007/s10143-023-02011-6.


ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer.

Wong A, Grobler A, Le B Contemp Clin Trials Commun. 2022; 30:101036.

PMID: 36407843 PMC: 9672918. DOI: 10.1016/j.conctc.2022.101036.